|
Group
| |
Number of patients
|
MPAP
|
SD
|
Systolic Regression
|
R2
|
Diastolic Regression
|
R2
|
|---|
|
Normal
| |
83
| |
19
|
3.6
|
0.50 SPAP + 3.36
|
0.777
|
1.11DPAP + 4.00
|
0.976
|
|
Group 1
| |
135
| |
50
|
12,8
|
0.58 SPAP + 3.52
|
0.995
|
1.16DPAP + 9.68
|
0.995
|
| |
IPAH
| |
68
|
51
|
11,2
|
0.60 SPAP + 2.35
|
0.838
|
1.10DPAP + 11.6
|
0.878
|
| |
Medication induced PAH
| |
10
|
51
|
13,9
|
0.61 SPAP + 0.02
|
0.991
|
1.44DPAP+ 0.43
|
0.989
|
| |
Cirrhosis
| |
15
|
52
|
12,5
|
0.60 SPAP −0.06
|
0.990
|
1.45DPAP + 1.07
|
0.986
|
| |
Congenital
| |
13
|
57
|
16,8
|
0.61 SPAP −1.03
|
0.986
|
1.44DPAP + 1.50
|
0.976
|
| |
Systemic sclerosis
|
22
|
44
|
12,5
|
0.61 SPAP + 1.65
|
0.966
|
1.10DPAP + 4.07
|
0.939
|
| |
HIV
| |
2
|
62
|
a
| | | | |
| |
Hereditary
| |
1
|
49
|
a
| | | | |
| |
schistosomiasis
|
1
|
50
|
a
| | | | |
| |
veno-occlusive disease
|
3
|
47
|
a
| | | | |
|
Group 2
| |
109
| |
38
|
10,8
|
0.59 SPAP + 3.57
|
0.877
|
1.25 DPAP + 3.25
|
0.867
|
|
Group 3
| |
26
| |
39
|
9,4
|
0.54 SPAP+ 5.62
|
0.908
|
1.31 DPAP + 1.75
|
0.877
|
|
Group 4
| |
63
| |
44
|
10.4
|
0.53 SPAP + 3.93
|
0.789
|
1.12 DPAP + 11.50
|
0.987
|
|
Group 5
| |
12
| |
44
|
11,04
|
0.53 SPAP + 6.38
|
0.976
|
1.45 DPAP-0.20
|
0.856
|
|
Unclassifed
| |
1
| |
43
|
a
|
a
|
a
|
a
|
a
|
-
IPAH idiopathic pulmonary arterial hypertension, MPAP mean pulmonary arterial pressure, SPAP systolic pulmonary arterial pressure, DPAP diastolic pulmonary arterial pressure, SD standart deviation
- MPAP is expressed in mmHg
-
awhere calculations are not applicable
